CompletedNot applicableNCT00004414
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
Studying Parenteral nutrition-associated cholestasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Michigan
- Principal Investigator
- Daniel Hillel Teitelbaum, MDUniversity of Michigan
- Intervention
- sincalide(drug)
- Enrollment
- 252 enrolled
- Eligibility
- All sexes
- Timeline
- 1997 – 2002
Study locations (6)
- Johns Hopkins Oncology Center, Baltimore, Maryland, United States
- University of Michigan Medical School, Ann Arbor, Michigan, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- Baylor University Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00004414 on ClinicalTrials.govOther trials for Parenteral nutrition-associated cholestasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06274788Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven TreatmentFresenius Kabi
- RECRUITINGPHASE4NCT06049680Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult PatientsFresenius Kabi
See all trials for Parenteral nutrition-associated cholestasis →